Clinical trials: Skin Diseases, Viral
Herpes Genitalis
A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons
This clinical research study will be an international trial evaluating the safety and effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression of repeated genital herpes infections in…
- Trial name
- NCT00079911
- Testing
- valacyclovir hydrochloride
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
Virus Diseases, Herpes Zoster
Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles
Chronic viral infections induce oxidative stress that can cause a number of concomitant diseases, e.g. cardio-vascular diseases or metabolic disorders.
- Trial name
- 168 (NCT00921934)
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Solid Tumor
A Study of ASP1012 in Adults With Solid Tumors
ASP1012 is a type of virus called an oncolytic virus which is used to treat some cancers. ASP1012 was changed in a laboratory to infect and kill cancer cells, leaving healthy cells alone.
- Trial name
- NCT06171178
- Testing
- ASP1012, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy
Drug-Drug Interaction Study: ASP2151 and Midazolam
CYP3A4 is involved in the metabolism of many drugs. So, it is important to assess in vivo the induction effect of ASP2151 on that enzyme to determine the extent of any possible drug interactions.
- Trial name
- NCT02403635
- Testing
- Midazolam, ASP2151
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Warts
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks.
- Trial name
- NCT00116662
- Testing
- Resiquimod
- Where
- 10 sites in United States
- Volunteers
- 84 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Melanoma, Merkel Cell Carcinoma
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT03901573
- Testing
- NT-I7, atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- NeoImmuneTech
HPV Infection, HPV-Related Carcinoma
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
- Conditions
- HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia, Genital Wart
- Trial name
- NCT06756269
- Testing
- Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, 9-HPV vaccine
- Where
- China
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Dermatitis, Melanoma (Skin Cancer)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
This study aims to determine if an artificial intelligence (AI) medical device can help doctors more accurately identify a wide variety of skin conditions and improve the efficiency of patient consultations.
- Conditions
- Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria
- Trial name
- LegitHealthSAN (NCT07428954)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- AI Labs Group S.L
Melanoma
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Treatment of subjects who have metastatic melanoma that expresses an activated mutant form of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib, and the Cytotoxic T Lymphocyte Antigen 4…
- Trial name
- NCT01400451
- Testing
- Ipilimumab (BMS-734016), Vemurafenib
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Bristol-Myers Squibb
Healthy
Drug-Drug Interaction Study: ASP2151 and Ritonavir
ASP2151 is an experimental treatment for herpes. HIV infected people are susceptible to contracting other infections because of their compromised immune system.
- Trial name
- NCT02223351
- Testing
- ASP2151, ritonavir
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
WHIM Syndrome
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
This natural history study is a prospective and retrospective, observational study of WHIM patients. WHIM syndrome is a rare, genetic, primary immunodeficiency disorder (a disorder in which the body's immune system does not…
- Trial name
- NCT03087370
- Testing
- No intervention
- Sponsor
- X4 Pharmaceuticals
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Herpes Simplex
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI).
- Trial name
- NCT05298254
- Testing
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Condylomata Acuminata
Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts
The purpose of this study is to investigate the clinical efficacy, safety and tolerability of a Polyphenon E Ointment 10% and a Polyphenon E Ointment 15% in the treatment of external genitial warts in male and female patients.
- Trial name
- NCT00449982
- Testing
- Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 480 people
- Sponsor
- MediGene
Herpes Labialis
Study to Evaluate Using a Cold Sore Patch to Treat Herpes Labialis
The primary objective of this study was to evaluate the safety and performance of a cold sore patch for the treatment of herpes labialis.
- Trial name
- NCT01208298
- Testing
- Cold Sore Patch
- Where
- 2 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Herpes Labialis
A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis
Recurrent herpes labialis are usually a minor malady of limited duration, although they are often painful and are uniformly discomforting for patients.
- Trial name
- NCT02207881
- Testing
- VDO gel
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Warts
Study With a Topical Gel to Treat Common Warts in Adults
The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks.
- Trial name
- NCT00117871
- Testing
- Resiquimod
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Graceway Pharmaceuticals, LLC